Stay updated with breaking news from Nsclc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Panelists discuss the intricacies of treating uncommon EGFR mutations, dissecting approved treatment options, considerations for specific mutations, and insights into the evolving drug landscape.
Shared insight into the transformative impact of targeted therapies in lung cancer treatment, from adjuvant therapy breakthroughs to emerging trials, emphasizing the critical role of comprehensive molecular testing.
Explore the complexities of limited molecular genotyping availability, the importance of comprehensive testing, and challenges in accessing target therapies, including cost considerations, in real-world clinical practice.
The phase 3 KEYLYNK-008 trial evaluating pembrolizumab plus olaparib in patients with metastatic squamous non–small cell lung cancer will be discontinued for futility, according to an announcement from Merck.
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.